Bioventus plans to launch Durolane, which has been available in over 25 countries for more than 15 years, in the US in early 2018.
The Food and Drug Administration (FDA) has approved Durolane for the treatment of pain associated with knee osteoarthritis. Durolane is a single-injection, hyaluronic acid (HA) product used for joint lubrication.
In clinical trials, treatment with Durolane effectively relieved pain and restored function for up to 6 months in patients with knee osteoarthritis.
Bioventus plans to launch Durolane, which has been available in over 25 countries for more than 15 years, in the US in early 2018.
Continue Reading
The Company has already launched 2 other products for the treatment of osteoarthritis: 3-injection HA Gelysin-3 and 5-injection HA Supartz FX.
Enjoying our content?
Thanks for visiting Rheumatology Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Rheumatology Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.